October 9, 2018 / 8:29 PM / 6 days ago

BRIEF-Obseva SA Presents Clinical Data From Phase III Implant 2 Trial Of Nolasiban In IVF At ASRM

Oct 9 (Reuters) -

* PRESENTS CLINICAL DATA FROM PHASE III IMPLANT 2 TRIAL OF NOLASIBAN IN IVF AT AMERICAN SOCIETY OF REPRODUCTIVE MEDICINE (ASRM) ANNUAL MEETING

* NOLASIBAN TREATMENT SHOWN TO SIGNIFICANTLY INCREASE LIVE BIRTH RATE IN RANDOMIZED CLINICAL TRIAL OF PATIENTS UNDERGOING IN VITRO FERTILIZATION

* SECONDARY ENDPOINT OF MISCARRIAGE RATE FROM WEEKS 2 TO 24 OF GESTATION SHOWED A FAVOURABLE IMPACT FROM NOLASIBAN TREATMENT

* OBSEVA-TOLERABILITY AND SAFETY PROFILE OF NOLASIBAN COMPARABLE TO PLACEBO, NO INCREASE IN SERIOUS ADVERSE EVENTS, IN ECTOPIC PREGNANCY, NOR IN CONGENITAL BIRTH DEFECTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below